Liquidia Technologies is trading 4.4% down at $24.77 as investors continue weighing the September 30 Delaware ruling on Yutrepia patents. - The ruling found two Yutrepia patent claims valid and infringed; Liquidia plans to appeal and seek removal of the PH-ILD indication from the label. - On October 7, the S&P 500, Nasdaq and Dow were down, while biotech was under pressure. - No new company announcement was identified today.